SAN FRANCISCO–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patie… […]
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson, Ph.D., group vice president, clinical development and exter… […]
SAN FRANCISCO, Jan. 24, 2020 (GLOBE NEWSWIRE) — Sun BioPharma, Inc. (OTCQB: SNBP), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, today summarized initial Phase 1 cl… […]
Back in November, the Department of Health and Human Services took the rare step of filing a complaint against Gilead for infringing on government-owned patents related to the HIV drug Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-expos… […]
→ Less than a year ago Gilead‘s antiviral remdesivir failed to make the cut as investigators considered a raft of potential drugs that could be used against an Ebola outbreak. But it may gain a new mission with the outbreak of the coronavirus in China,… […]
A year into his tenure, here’s how Daniel O’Day is changing the biotech.
David Moller
→ After passing their third straight Phase III trial for its new kind of diabetes tablet in Japan, French pharma Poxel has tapped David Moller as CSO. Moller has focused his career in the fields of diabetes and metabolic disorders. He most… […]
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treat… […]
Home DNA-testing unicorn 23andMe Inc. is letting go of about 100 people — 14 percent of its workforce — amid a drop in business.
CEO Anne Wojcicki told CNBC that she is surprised by declining demand for her Sunnyvale company’s genetic tests.
“This h… […]
In the latest sign of a slump in consumer genetic testing, 23andMe is laying off 14% of its workforce amid falling sales of its DNA spit kits. […]
© 2019 San Francisco Biotechnology Network
